(Q35026059)

5 August 2017

title

Is there still a role for neoadjuvant therapy in breast cancer? (English)

1 reference

5 August 2017

Catherine Shannon

1

1 reference

5 August 2017

Ian Smith

series ordinal

2

1 reference

5 August 2017

publication date

1 January 2003

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

45

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

77-90

1 reference

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Multimodal treatment of locoregionally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Primary medical therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Primary systemic therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neoadjuvant chemotherapy in 126 operable breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Treatment of early localized breast cancer in elderly patients by Tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Tamoxifen as sole therapy for primary breast cancer in the elderly patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Indications for primary tamoxifen therapy in elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Treatment of breast cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Preoperative chemotherapy induces apoptosis in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900091-4

7 January 2021

10.1016/S1040-8428(02)00091-4

Identifiers

DOI

1 reference

5 August 2017

1 reference